Viewing Study NCT04168502


Ignite Creation Date: 2025-12-25 @ 3:54 AM
Ignite Modification Date: 2026-01-09 @ 9:39 PM
Study NCT ID: NCT04168502
Status: RECRUITING
Last Update Posted: 2024-11-08
First Post: 2019-11-11
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML
Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module